WINSTON-SALEM, N.C. – Inmar Intelligence, a data-driven technology-enabled services company, today announced an agreement with Protenus, the healthcare compliance analytics platform that protects patient privacy for the nation’s leading health systems, will expand drug diversion prevention capabilities to Inmar Intelligence’s clients within U.S. health systems. Through this agreement, Protenus has joined Inmar Intelligence’s Innovator Ecosystem as a Platform Accelerator.  The Innovator Ecosystem brings together companies that deliver technological innovation to the marketplace, improve ROI for retailers,CPGs, and Healthcare Facilities and enhance the customer experience.
The opioid epidemic continues to be a major health crisis in the U.S., but conversations around the topic have dwindled in light of the COVID-19 pandemic. In fact, prior to COVID-19, over 220 people died from an opioid overdose per day, and this number has only increased since the pandemic began. However, safeguards against improper distribution and misuse of controlled substances, including opioids, remain strong and a driving force behind protecting patients and the U.S. healthcare workforce.

“In working with Protenus, our Inmar Intelligence healthcare clients have the opportunity to implement Protenus’ drug diversion prevention platform and strengthen their systems to prevent overdoses, protect patients and employees, and mitigate the risk of establishing negative institutional reputations,” said Rob Zomok, president, SupplyTech, at Inmar Intelligence. “We look forward to integrating Protenus’ platform into our Innovator Ecosystem and our client systems, and are proud of our combined role in helping to solve the opioid crisis across the U.S.”

Protenus’ Clinical Drug Diversion Surveillance powered by AI capabilities tracks actions and movements within a hospital’s EHR and ancillary systems, identifying unusual activity that could otherwise lead to unauthorized distribution of controlled substances, including opioid medications, inside and outside the facility. The advanced analytics detect potential threats to patients, healthcare workers and all of those directly and tangentially related from potential harm due to the unauthorized use of the medications.

“Inmar Intelligence has a decades-long proven track record of addressing national health issues head on. We are thrilled to be working with Inmar to combine the best-in-class offerings and protect not only those in the health systems across the country, but their families as well,” said Nick Culbertson, CEO and Co-founder of Protenus. “This agreement allows us to reach more health care systems across the country, and in turn, help protect more Americans from harm.”

For more information about Inmar Intelligence, please visit www.inmar.com. For more information about Protenus, please visit www.protenus.com.